The Use of Esketamine in CT-guided Percutaneous Liver Tumor Ablation Reduces the Consumption of Opioids: A Randomized, Controlled, Double-blind Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049152

Enrollment

Unknown

Registered

2021-07-23

Start date

2020-12-01

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Tumor

Interventions

A:none

B:Esketamine 0.1mg/ kg i.v

C:Esketamine 0.2mg/ kg i.v

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. scheduled for CT-guided percutaneous liver tumor ablation; 2. ASA I or II; 3. aged 18 to 65 years old; 4. The number of liver tumor no more than 3; 5. the operation time should less than 3 hours; 6. the renal function should be normal and the Child-Pugh score of liver function should be Grade A; 7. patients signed informed consent before operating; 8. had not participated in other clinical drug trials in the last month.

Exclusion criteria

Exclusion criteria: 1. patients with mental illness; 2. patients who had received more than 3 times of ablation treatment before; 3. drinking patients; 4. hypertension patients with poor blood pressure control or without regular treatment; 5. patients with glaucoma, intracranial tumor or cerebrovascular disease; 6. patients allergic to the components of the study drug; 7. patients with long term use of sedatives and analgesics; 8. patients who had suffered acute upper respiratory infection in recent 2 weeks.

Design outcomes

Primary

Measure	Time frame
the total dosage of Remifentanil;	—

Secondary

Measure	Time frame
VAS score;	—

Countries

China

Contacts

Public ContactWan Huang

Sun Yat-sen University Cancer Center

huangwan@sysucc.org.cn+86 020-87343060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026